Biomea Fusion Inc — Liquidità (NASDAQ:BMEA)

Financials

Flusso di cassa derivante dalle attività operative -35.44 M-62.42 M-96.59 M-119.89 M-70.37 M -70.37 M Flussi di cassa derivanti dalle attività di investimento -33.35 M27.34 M-2.22 M-362 K-362 K — Liquidità derivante dalle attività di finanziamento 153.19 M1.24 M163.8 M1.67 M67.9 M 67.9 M Liquidità libera -38.61 M-63.45 M-99.96 M-120.26 M-70.37 M -70.37 M

Notizie

Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes Transcript

Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity Transcript

Biomea Fusion, Inc. (BMEA) Presents at 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 - Slideshow (NASDAQ:BMEA) 2026-03-16

Biomea Fusion, Inc. (BMEA) Presents at The Citizens Life Sciences Conference 2026 - Slideshow (NASDAQ:BMEA) 2026-03-12

Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:BMEA) 2026-01-16

Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Rodman & Renshaw avvia la copertura di Biomea Fusion con rating Buy

Rodman & Renshaw initiates Biomea Fusion stock with Buy rating

Biomea Fusion delinea i piani di sviluppo di farmaci per diabete e obesità per il 2026

Biomea Fusion outlines 2026 diabetes and obesity drug development plans

Il titolo di Biomea Fusion sale dopo risultati duraturi sul trattamento del diabete

Biomea Fusion stock soars after durable diabetes treatment results